|
Affiliation |
Director |
|
Laboratory Address |
5200 Kihara-Kiyotake-cho, Miyazaki City |
|
Laboratory Phone number |
+81-985-85-2968 |
|
Laboratory Fax number |
+81-985-85-6958 |
|
Homepage |
|
|
External Link |
|
KAMOTO Toshiyuki
|
|
|
Degree 【 display / non-display 】
-
博士（医学） ( 1997.7 京都大学 )
-
学士（医学） ( 1987.3 京都大学 )
Research Interests 【 display / non-display 】
-
urology, uro-oncology, laparoscopic surgery
-
腫瘍マーカー
-
腎移植
-
精巣癌
-
泌尿器腫瘍学
-
前立腺癌
-
内視鏡/体腔鏡手術
Research Areas 【 display / non-display 】
-
Life Science / Urology / urologic oncology
Education 【 display / non-display 】
-
Kyoto University Graduate School, Division of Medicine
- 1995.8
Country：Japan
-
Kyoto University Faculty of Medicine
- 1987.3
Country：Japan
Campus Career 【 display / non-display 】
-
University of Miyazaki Faculty of Medicine School of Medicine Department of Developmental and Urological-Reproductive Medicine, Urology Professor
2009.05 - 2024.09
-
University of Miyazaki Director
2024.10 - Now
-
University of Miyazaki Faculty of Medicine
2021.10 - 2024.09
-
University of Miyazaki Faculty of Medicine College Hospital
2016.04 - 2024.09
-
University of Miyazaki Faculty of Medicine
2015.10 - 2021.09
External Career 【 display / non-display 】
-
University of Miyazaki Faculty of Medicine School of Medicine Surgery study course urology study field Professor
2009.5
-
京都大学大学院医学研究科 器官外科学講座 泌尿器科学 准教授
2007.4 - 2009.4
-
京都大学大学院医学研究科 器官外科学講座 泌尿器科学 助教授
2003.11 - 2007.3
-
京都大学大学院医学研究科 器官外科学講座 泌尿器科学 講師
2001.10 - 2003.10
-
京都大学医学部附属病院 泌尿器科 助手
1997.1 - 2001.9
Professional Memberships 【 display / non-display 】
Papers 【 display / non-display 】
-
Terada N, Mizowaki T, Saito T, Yokomizo A, Kohei N, Tabata KI, Shiota M, Takahashi A, Shimazui T, Goto T, Hashimoto Y, Fujii M, Tomida R, Sakurai T, Hashimoto K, Kawamura S, Teraoka S, Sakamoto S, Kimura T, Kamiyama M, Narita S, Tanaka N, Kato T, Kato M, Osawa T, Kojima T, Inoue T, Sugimoto M, Nishiyama H, Kamoto T, Japanese Urological Oncology Group.
BJUI compass 1 ( 5 ) 165 - 173 2020.11
Authorship：Last author Language：English Publishing type：Research paper (scientific journal) Publisher：BJUI Compass
Objectives: To evaluate the association between the use of local radiotherapy (RT) with the survival of patients with de novo metastatic prostate cancer and symptomatic local events (SLEs). Patients and methods: Patients were initially diagnosed with metastatic prostate cancer between 2008 and 2017 at 30 institutes in Japan. Prostate-specific antigen (PSA) progression-free survival (PSA-PFS) under initial androgen deprivation therapy and overall survival (OS) was compared between patients receiving local RT (RT group) and no RT (no-RT group) by multivariate Cox proportional hazard analyses. The occurrence rate of grade ≥2 SLEs was compared by multivariate logistic regression analyses. Propensity score matching (PSM) analyses were performed to compare PSA-PFS and OS of the groups in the high and low metastatic burden cohort. Results: Two hundred and five (7%) of 2829 patients received RT before PSA progression. Median PSA-PFS and OS were significantly longer in the RT group than in the no-RT group and the difference was significant in multivariate analyses (HR = 0.44, 95% CI = 0.33-0.57 and HR = 0.40, 95% CI = 0.27-0.60, respectively). The occurrence rate of grade ≥2 SLEs was significantly lower in the RT group (2%) than the no-RT group (9%) and the difference was significant in multivariate analyses (HR = 0.28, 95% CI = 0.10-0.76). Using PSM analyses, PSA-PFS and OS remained significantly different (HR = 0.64, 95% CI = 0.46-0.89 and HR = 0.47, 95% CI = 0.30-0.72, respectively), between the RT (n = 182) and the no-RT (n = 182) groups. The difference in OS was significant in the high metastatic burden cohort (HR = 0.55, 95% CI = 0.37-0.81). Conclusions: Addition of local RT to standard treatment for de novo metastatic prostate cancer patients tends to have the potential to extend survival, even in patients with high metastatic burden, and to reduce SLEs.
DOI： 10.1002/bco2.35
-
Wakimura N., Nagayasu M.A., Tanaka H., Murashima T., Fujii M., Nagai T., Mukai S., Kamoto T.
Journal of Medical Case Reports 19 ( 1 ) 2025.12
Publishing type：Research paper (scientific journal) Publisher：Journal of Medical Case Reports
Introduction: Mixed sex cord stromal tumor is defined as a tumor consisting of various combinations of sex cord stromal elements, and the tumor is extremely rare. Case presentation: A 76-year-old Japanese male visited our hospital complaining of left scrotal swelling. Magnetic resonance imaging of the mass showed a multilocular cystic pattern with different degrees of intensities in each cyst. The solid component was observed in part showing hypointensity on the T2-weighted image. Although there was no apparent evidence of malignancy in cytology of punctured fluid of the cystic tumor, malignant potential was not ruled out completely. Therefore, transinguinal radical orchiectomy was performed, and the tumor was diagnosed as mixed sex cord stromal tumor consisting of adult-type granulosa cell tumor, Leydig cell tumor and Sertoli cell tumor components. The patient recovered without any postoperative event. In addition, neither apparent recurrence nor metastasis was observed at 7 years after surgery. Conclusion: The tumor showed a multilocular cystic appearance with solid component, which was similar in appearance to previous reports of the same pathological features. Pathological findings of each component were compatible with those of mixed sex cord stromal tumor, and immunohistochemical analysis was useful for accurate diagnosis. The tumor was successfully resected, and no apparent recurrence was observed at 7 years after surgery.
-
Engineered Expression of Hepatocyte Growth Factor Activator Inhibitor-1 (HAI-1) Reduces the Growth of Bladder Cancer Cells. Reviewed
Katayama Y, Akioka T, Kimura S, Fujii M, Nagai T, Kiwaki T, Kawaguchi M, Fukushima T, Sato Y, Mukai S, Kamoto T, Sawada A
Biomedicines 13 ( 4 ) 2025.4
Language：English Publishing type：Research paper (scientific journal)
-
Phosphorylation of MET Is Upregulated in Metastatic Sites of Renal Cell Carcinoma: Possible Role of MET and Hepatocyte Growth Factor Activation-Targeted Combined Therapy. Reviewed
Akioka T, Kimura S, Katayama Y, Fujii M, Kiwaki T, Kawaguchi M, Fukushima T, Sato Y, Mukai S, Kamoto T, Sawada A
Biomedicines 13 ( 4 ) 2025.3
Language：English Publishing type：Research paper (scientific journal)
-
Kimura S., Iwano S., Akioka T., Kuchimaru T., Kawaguchi M., Fukushima T., Sato Y., Kataoka H., Kamoto T., Mukai S., Sawada A.
International Journal of Molecular Sciences 26 ( 5 ) 2025.3
Language：English Publishing type：Research paper (scientific journal) Publisher：International Journal of Molecular Sciences
The liver is the most lethal metastatic site in castration-resistant prostate cancer (CRPC). Overexpression of MET protein has been reported in CRPC, and MET is an important driver gene in androgen-independent CRPC cells. Mouse CRPC cell line CRTC2 was established by subcutaneous injection of hormone-sensitive PC cells (TRAMP-C2) in castrated nude mice. CRCT2/luc2 cells were injected into the spleen of castrated nude mice, and liver metastasis was confirmed at 2 weeks post-injection. We administered MET inhibitor (MET-I) and HGF activator inhibitor (HGFA-I) to this liver metastasis model and assessed the therapeutic effect. After intrasplenic injection, CRTC2 showed a higher incidence of liver metastasis whereas no metastasis was observed in TRAMP-C2. Microarray analysis revealed increased expression of HGF, MET, and HPN, HGFAC (encoding HGF activating proteases) in liver metastasis. Proliferation of CRCT2 was significantly inhibited by co-administration of MET-I and HGFA-I by in vitro analysis with HGF-enriched condition. In an analysis of the mouse model, the combination-therapy group showed the strongest reduction for liver metastasis. Immunohistochemical staining also revealed the strongest decrease in phosphorylation of MET in the combination-therapy group. Co-culture with HGF-expressed mouse fibroblasts showed attenuation of the inhibitory effect of MET-I; however, additional HGFA-I overcame the resistance. We established an androgen-independent CRPC cell line, CRTC2, and liver metastasis model in mice. Significant effect was confirmed by combined treatment of MET-I and HGFA-I by in vitro and in vivo analysis. The results suggested the importance of combined treatment with both MET- and HGF-targeting agents in the treatment of HGF-enriched conditions including liver metastasis.
DOI： 10.3390/ijms26052308
Books 【 display / non-display 】
-
賀本 敏行, 都築 豊徳（ Role： Sole author）
総合医学社 2021 （ ISBN:9784883787203 ）
-
高橋 悟, 賀本 敏行, 菊地 栄次, 杉本 幹史, 安井 孝周, 赤座 英之（ Role： Sole author）
医学図書出版 2021 （ ISBN:9784865174519 ）
Language：Japanese Book type：Scholarly book
-
今日の診療のためにガイドライン外来診療2015
泉孝英、他（ Role： Joint author）
日経メディカル開発 2015.3
Language：Japanese Book type：Scholarly book
-
国試カンファレンス あなむね
賀本敏行、神波大己、他（ Role： Joint author）
医学評論社 2014.6
Language：Japanese Book type：Scholarly book
-
第109回医師国家試験問題解説書
賀本敏行、他（ Role： Joint author）
医学評論社 2014.4
Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
Future direction of urologic surgery - What should we learn from the change of surgical procedure
Kamoto T., Sugimoto M.
Nishinihon Journal of Urology 82 ( 1 ) 3 - 4 2020.4
Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Nishinihon Journal of Urology
-
【なぜそれが大切?術式別観察ポイントとその根拠】 尿管皮膚瘻造設術の観察ポイントとその根拠
向井尚一郎, 深尾理, 賀本敏行
泌尿器ケア 17 ( 10 ) 985 - 989 2012.10
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：メディカ出版
-
【泌尿器病理I-前立腺と腎臓-】 今日の前立腺癌の治療法
月野浩昌, 賀本敏行
病理と臨床 30 ( 9 ) 941 - 948 2012.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：文光堂
-
【明日を見据えた前立腺癌診療】 Key words 前立腺癌の今後の薬物療法への期待
賀本敏行
カレントテラピー 30 ( 9 ) 968 - 969 2012.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：ライフメディコム
-
【骨転移のマネジメント】 前立腺癌治療と骨転移マネジメント
賀本敏行
癌と化学療法 39 1178 - 1182 2012.7
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：癌と化学療法社
Presentations 【 display / non-display 】
-
進行性/去勢抵抗性前立腺癌治療に於ける骨マネジメントー骨転移治療のポイントは？－
賀本敏行
第69回西日本泌尿器科学会総会
Event date： 2017.11.9 - 2017.11.12
Language：Japanese Presentation type：Public lecture, seminar, tutorial, course, or other speech
-
Differential use of chemotherapy and novel hormone therapy for castration-resistant prostate cancer
賀本敏行
第15回日本臨床腫瘍学会学術集会
Event date： 2017.7.27 - 2017.7.29
Language：Japanese Presentation type：Symposium, workshop panel (nominated)
-
Update on Prostate Cancer Biopsy Reporting International conference
賀本敏行
Advancements in Urology 2017 in San Diego
Event date： 2017.1.11 - 2017.1.14
Language：Japanese Presentation type：Public lecture, seminar, tutorial, course, or other speech
-
泌尿器細胞診報告様式 2015 に沿った細胞診断ーリスクの検証ー
賀本敏行
第55回日本臨床細胞学会秋季大会
Event date： 2016.11.19
Language：Japanese Presentation type：Symposium, workshop panel (nominated)
-
去勢抵抗性前立腺癌とは
賀本敏行
日本病理学会第 10 回診断病理サマーフェスト
Event date： 2016.9.4
Language：Japanese Presentation type：Oral presentation (invited, special)
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
転移性CRPCにおける、HGF/METパスウェイを標的とした新規治療法の開発
Grant number：23K08737 2023.04 - 2026.03
独立行政法人日本学術振興会 科学研究費基金 挑戦的研究(萌芽)
Authorship：Principal investigator
-
ヒト化マウスを用いた腎細胞癌PDXモデルの樹立とMET阻害薬効果予測因子の同定
Grant number：22K09506 2022.04 - 2025.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(C)
Authorship：Coinvestigator(s)
-
CRPCにおけるCAVEOLIN-1,2関連シグナルを介した新規治療法の探索
Grant number：15K10597 2015.04 - 2018.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
去勢抵抗性前立腺癌に対するCAVEOLINを介する新規治療法を開発する。
-
進行性前立腺癌における新しい治療ターゲットの探索
Grant number：24592398 2012.04 - 2015.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
進行性前立腺癌における新しい治療ターゲットの探索
Past consigned research fund received 【 display / non-display 】
-
A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
2018.08 - 2022.04
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer
2017.04 - 2022.11
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormonesensitive Prostate Cancer (mHSPC)
2016.02 - 2022.03
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 inCombination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
2015.10 - 2021.12
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
2015.04 - 2021.03
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
Available Technology 【 display / non-display 】
-
泌尿器科領域悪性腫瘍における浸潤・転移機構の解明
腎無形成マウスモデルを使用した尿管芽浸潤障害 (FUBI)の解明
宮崎泌尿器科がんデータベース(MUCD)を用いたがん診断と治療の検証Related fields where technical consultation is available：泌尿器がんおよび泌尿器疾患の臨床データ、臨床サンプルの収集
泌尿器がんのゼノグラフトモデル（PDX）の作製
骨転移マウスモデルの作製Message：泌尿器腫瘍は基本的に高齢者の悪性腫瘍であり、高齢化に従って患者数、死亡者数は右肩上がりです。実際の患者さんのデータベースと、基礎研究の融合を目指しています。
Committee Memberships 【 display / non-display 】
-
日本泌尿器科学会 理事
2019.4
Committee type：学協会
NCD運営委員会委員長